Industry Strength Score
56/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
AMGEN INC (AMGN) Stock Price & Overview
NASDAQ:AMGN • US0311621009
Current stock price
329.82 USD
-16.43 (-4.75%)
At close:
329.57 USD
-0.25 (-0.08%)
After Hours:
The current stock price of AMGN is 329.82 USD. Today AMGN is down by -4.75%. In the past month the price decreased by -5.21%. In the past year, price increased by 17.28%.
AMGN Key Statistics
52-Week Range261.43 - 391.29
Current AMGN stock price positioned within its 52-week range.
1-Month Range324.63 - 359.445
Current AMGN stock price positioned within its 1-month range.
- Market Cap
- 178.001B
- P/E
- 14.92
- Fwd P/E
- 13.88
- EPS (TTM)
- 22.10
- Dividend Yield
- 2.98%
AMGN Stock Performance
Today
-4.75%
1 Week
-4.28%
1 Month
-5.21%
3 Months
-3.53%
Longer-term
6 Months +10.52%
1 Year +17.28%
2 Years +7.84%
3 Years +49.48%
5 Years +38.61%
10 Years +108.81%
AMGN Stock Chart
AMGN Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to AMGN. When comparing the yearly performance of all stocks, AMGN turns out to be only a medium performer in the overall market: it outperformed 52.25% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
AMGN Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to AMGN. While AMGN belongs to the best of the industry regarding profitability, there are concerns on its financial health.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
AMGN Earnings
On April 30, 2026 AMGN reported an EPS of 5.15 and a revenue of 8.62B. The company beat EPS expectations (6.15% surprise) and missed revenue expectations (-1.52% surprise).
Next Earnings DateN/A
Last Earnings DateApr 30, 2026
PeriodQ1 / 2026
EPS Reported$5.15
Revenue Reported8.618B
EPS Surprise 6.15%
Revenue Surprise -1.52%
AMGN Forecast & Estimates
43 analysts have analysed AMGN and the average price target is 362.37 USD. This implies a price increase of 9.87% is expected in the next year compared to the current price of 329.82.
For the next year, analysts expect an EPS growth of 4.51% and a revenue growth 4.12% for AMGN
Analysts
Analysts70.7
Price Target362.37 (9.87%)
EPS Next Y4.51%
Revenue Next Year4.12%
AMGN Index Membership
AMGN is currently included in the following stock indexes tracked on ChartMill.
AMGN Financial Highlights
Over the last trailing twelve months AMGN reported a non-GAAP Earnings per Share(EPS) of 22.1. The EPS increased by 6.45% compared to the year before.
Income Statements
Revenue(TTM)36.75B
Net Income(TTM)7.71B
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 20.98% | ||
| ROA | 8.51% | ||
| ROE | 89.06% | ||
| Debt/Equity | 5.78 |
Chartmill High Growth Momentum
EPS Q2Q%5.1%
Sales Q2Q%5.76%
EPS 1Y (TTM)6.45%
Revenue 1Y (TTM)9.95%
AMGN Ownership
Ownership
Inst Owners85.27%
Shares539.69M
Float538.41M
Ins Owners0.07%
Short Float %2.37%
Short Ratio4.93
AMGN Industry Overview
AMGN operates in the Biotechnology sub-industry within the Health Care sector. This group contains 416 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
13/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
26%
Outperformed 26% of sub-industries
3 Month Rank
50%
Outperformed 50% of sub-industries
6 Month Rank
32%
Outperformed 32% of sub-industries
Industry Fundamentals & Breadth
- Members
- 416
- New Highs
- 5.1%
- New Lows
- 4.6%
- Average ROE
- 48.5%
- Average Profit Margin
- 20.5%
- Average Operating Margin
- 33.6%
- Average P/E
- 22.9
- Average Fwd P/E
- 18.2
- Average Debt/Equity
- 2.2
AMGN Latest News, Press Relases and Analysis
2 days ago - By: Chartmill
AMGN Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 12.59 | 373.774B | ||
| GILD | GILEAD SCIENCES INC | 14.89 | 162.401B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.77 | 108.708B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.72 | 74.75B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 27.54 | 41.295B | ||
| INSM | INSMED INC | N/A | 29.427B | ||
| NTRA | NATERA INC | N/A | 29.219B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 28.56B | ||
| BIIB | BIOGEN INC | 11.44 | 27.779B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.52 | 25.042B | ||
| INCY | INCYTE CORP | 10.61 | 18.96B | ||
| MRNA | MODERNA INC | N/A | 18.219B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About AMGN
Company Profile
Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company is headquartered in Thousand Oaks, California and currently employs 31,500 full-time employees. The company discovers, develops, manufactures and delivers medicines for the toughest diseases. The company focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. The company operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. The company markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. The company markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. The company markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.
Company Info
IPO: 1983-06-17
AMGEN INC
One Amgen Center Drive
Thousand Oaks CALIFORNIA 91320 US
CEO: Robert A. Bradway
Employees: 31500
Phone: 18009279800
AMGEN INC / AMGN FAQ
Can you describe the business of AMGEN INC?
Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company is headquartered in Thousand Oaks, California and currently employs 31,500 full-time employees. The company discovers, develops, manufactures and delivers medicines for the toughest diseases. The company focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. The company operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. The company markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. The company markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. The company markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.
What is the stock price of AMGEN INC today?
The current stock price of AMGN is 329.82 USD. The price decreased by -4.75% in the last trading session.
Does AMGEN INC pay dividends?
AMGEN INC (AMGN) has a dividend yield of 2.98%. The yearly dividend amount is currently 9.01.
What is the ChartMill rating of AMGEN INC stock?
AMGN has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
How is the market expecting AMGN stock to perform?
43 analysts have analysed AMGN and the average price target is 362.37 USD. This implies a price increase of 9.87% is expected in the next year compared to the current price of 329.82.
Can you provide the growth outlook for AMGEN INC?
The Revenue of AMGEN INC (AMGN) is expected to grow by 4.12% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the market cap for AMGEN INC?
AMGEN INC (AMGN) has a market capitalization of 178.00B USD. This makes AMGN a Large Cap stock.